Docking studies and development of novel 5-heteroarylamino-2,4-diamino-8-chloropyrimido-[4,5-b]quinolines as potential antimalarials

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 10, 2006, Pages 2613-2617

  Joshi, Advait A ^a   Viswanathan, C L ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

MOE Dock; P. falciparum glutathione reductase; Pyrimidoquinolines

Indexed keywords

ANTIMALARIAL AGENT; GLUTATHIONE REDUCTASE; PROTOZOAL PROTEIN; QUINOLINE DERIVATIVE;

ANTIMALARIAL ACTIVITY; ARTICLE; COMPUTER PROGRAM; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME BINDING; PHARMACOPHORE; PLASMODIUM FALCIPARUM; PREDICTION; SCORING SYSTEM;

ANIMALS; ANTIMALARIALS; BINDING SITES; GLUTATHIONE REDUCTASE; MODELS, MOLECULAR; PLASMODIUM FALCIPARUM; QUINOLINES;

PLASMODIUM FALCIPARUM; RUMEX;

EID: 33645893172     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.02.038     Document Type: Article

References (6)

1. WHO World Malaria Report, 2005, World Health Organization, Geneva, Switzerland (http://rbm.who.int/wmr2005).
2. Joshi A.A., Narkhede S.S., and Viswanathan C.L. Bioorg. Med. Chem. Lett. 15 (2005) 73
3. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. Nucleic Acids Res. 28 (2000) 235
4. Molecular Operating Environment (MOE) 2003.02, Chemical Computing Group Inc., Quebec, Canada, 2003.
5. Andrews P.R., Craik D.J., and Martin J.L. J. Med. Chem. 27 (1984) 1648
6. Maginn S. Abstracts of papers, SMi's 3rd Annual Conference, The Hatton, London, February 23-24, 2004; SMi 11.40.